CDC Reports Rise in Pediatric Drug-Resistant Infections

Estimated carbapenemase-producing CRE incidence among U.S. children climbed 92% from 2019 to 2024, according to a CDC analysis.

Updated on Nov. 10, 2026 in Children’s Health

Plain glass petri dishes with pale amber agar and a steel microscope slide on a clean white laboratory bench under soft window light.
The CDC reported that estimated carbapenemase-producing drug-resistant infections among U.S. children rose 92% between 2019 and 2024, with NDM organisms overtaking KPC. AI Illustration. Upload story photo >

Live Poll

Do you trust your local hospitals to protect patients from drug-resistant infections?

A CDC analysis found that estimated national pediatric carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) incidence in the United States rose 92% from 2019 to 2024. NDM-producing organisms overtook KPC as the leading carbapenemase among pediatric isolates.

Why it matters

NDM enzymes are not inhibited by avibactam, vaborbactam, or relebactam, which removes several antibiotics commonly used against KPC-producing bacteria. The CDC has warned the rise in NDM-CRE threatens to increase estimated CRE infection and death totals.

The analysis drew on CRE isolates from patients under 18 submitted to the AR Lab Network between January 2019 and December 2024, with 109 of 129 incident cases completing chart review. Among reviewed patients, 14% had no healthcare risk factors, while 75% of those with risk factors had an underlying medical condition.

The players

Centers for Disease Control and Prevention (CDC)

The CDC is the U.S. federal public health agency that conducts surveillance and analysis of antibiotic-resistant infections, including the AR Lab Network.

The details

Investigators analyzed CRE isolates from patients younger than 18 years and estimated annual unadjusted incidence in a national convenience sample and in an open cohort of 29 states that require CRE isolate submission. Among infants and toddlers, cardiovascular disease was the most common underlying condition at 64%, and intensive care unit hospitalization was the most common exposure at 40%.

Timeline

  1. January 2019 to December 2024: study period for pediatric CRE isolate analysis.

  2. January 2023 through March 2024: period of incident CP-CRE cases reviewed via medical charts.

  3. November 4, 2026: CDC pediatric CP-CRE analysis published in JPIDS.

Health Landscape

The findings extend the CDC's AR Lab Network surveillance, which tracks resistant organisms nationally and has now documented NDM-producing bacteria overtaking KPC among U.S. pediatric isolates. The shift matters for treatment because NDM producers resist several newer beta-lactam/beta-lactamase inhibitor combinations that were developed against KPC.

Parents of children with recent hospitalizations, surgeries, or time in intensive care may want to ask clinicians about resistant-bacteria risk when antibiotics are prescribed. The NDM shift means some antibiotics used against older resistant strains may not work, which can affect treatment choices.

The takeaway

Infections from drug-resistant bacteria are increasingly tied to healthcare exposure in children, especially hospital intensive care and care received abroad. Asking providers about recent medical travel and hospital stays can help guide early testing and treatment decisions.

Further reading

For more on childhood illness trends, see Children's Health coverage on Wisevoter.com.

Source note: This article includes information reported by Contagionlive.

Live Poll

Do you trust your local hospitals to protect patients from drug-resistant infections?